Search Results - "Favours, Edward"

Initial testing (stage 1) of tazemetostat (EPZ‐6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program by Kurmasheva, Raushan T., Sammons, Melissa, Favours, Edward, Wu, Jianwrong, Kurmashev, Dias, Cosmopoulos, Katherine, Keilhack, Heike, Klaus, Christine R., Houghton, Peter J., Smith, Malcolm A.

“…Background Tazemetostat (EPZ‐6438) is a selective inhibitor of the histone methyltransferase EZH2 and currently in clinical development for non‐Hodgkin…”
Get full text

The pediatric preclinical testing program: Description of models and early testing results by Houghton, Peter J., Morton, Christopher L., Tucker, Chandra, Payne, Debbie, Favours, Edward, Cole, Claire, Gorlick, Richard, Kolb, E. Anders, Zhang, Wendong, Lock, Richard, Carol, Hernan, Tajbakhsh, Mimi, Reynolds, C. Patrick, Maris, John M., Courtright, Joshua, Keir, Stephen T., Friedman, Henry S., Stopford, Charles, Zeidner, Joseph, Wu, Jianrong, Liu, Tiebin, Billups, Catherine A., Khan, Javed, Ansher, Sherry, Zhang, Jian, Smith, Malcolm A.

“…Background The Pediatric Preclinical Testing Program (PPTP) is an initiative supported by the National Cancer Institute (NCI) to identify novel therapeutic…”
Get full text

Evaluation of the Antitumor Efficacy, Pharmacokinetics, and Pharmacodynamics of the Histone Deacetylase Inhibitor Depsipeptide in Childhood Cancer Models In vivo by Graham, Claire, Tucker, Chandra, Creech, Jeremy, Favours, Edward, Billups, Catherine A, Liu, Tiebin, Fouladi, Maryam, Freeman, 3rd, Burgess B, Stewart, Clinton F, Houghton, Peter J

“…Purpose: Histone acetyltransferases and histone deacetylases (HDAC) control the acetylation state of histones and other proteins regulating transcription and…”
Get full text

In vivo Evaluation of Ixabepilone (BMS247550), A Novel Epothilone B Derivative, against Pediatric Cancer Models by PETERSON, Jennifer K, TUCKER, Chandra, FAVOURS, Edward, CHESHIRE, Pamela J, CREECH, Jeremy, BILLUPS, Catherine A, SMYKLA, Richard, LEE, Francis Y. F, HOUGHTON, Peter J

“…Purpose: Vinca alkaloids, agents that cause depolymerization of microtubules, are highly active in treatment of many pediatric cancers. In contrast, taxanes,…”
Get full text

Evaluation of ABT-751 against childhood cancer models in vivo by Morton, Christopher L, Favours, Edward G, Mercer, Kimberly S, Boltz, Claire R, Crumpton, Jeri Carol, Tucker, Chandra, Billups, Catherine A, Houghton, Peter J

“…ABT-751 is a novel antimitotic agent that binds tubulin at the colchicine binding site. ABT-751 is undergoing Phase I trials in children, but has not been…”
Get full text

Abstract 3100: Nanoformulated Talazoparib and Olaparib for enhanced delivery by Baldwin, Paige, Kumar, Rajiv, Favours, Edward, Liby, Karen, Kurmasheva, Raushan, Kozono, David, Sridhar, Srinivas

“…Introduction: PARP inhibitors such as Talazoparib and Olaparib exploit deficiencies in DNA repair pathways, making them attractive candidates for treatment of…”
Get full text

Evaluation of entinostat alone and in combination with standard‐of‐care cytotoxic agents against rhabdomyosarcoma xenograft models by Kurmasheva, Raushan T., Bandyopadhyay, Abhik, Favours, Edward, Del Pozo, Vanessa, Ghilu, Samson, Phelps, Doris A., Erickson, Stephen W., Peer, Cody J., Figg, William D., Smith, Malcolm A., Houghton, Peter J.

“…Background Entinostat, a selective class I histone deacetylase inhibitor, has been reported to enhance the activity of cytotoxic agents and suppress expression…”
Get full text

Evaluation of VTP‐50469, a menin‐MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium by Kurmasheva, Raushan T., Bandyopadhyay, Abhik, Favours, Edward, Pozo, Vanessa Del, Ghilu, Samson, Phelps, Doris A., McGeehan, Gerard M., Erickson, Stephen W., Smith, Malcolm A., Houghton, Peter J.

“…Background VTP‐50469 is a potent inhibitor of the menin‐MLL1 interaction and is implicated in signaling downstream of EWSR1‐FLI1. Procedure VTP‐50469 was…”
Get full text

Abstract A137: Initial testing (Stage 1) of EPZ-6438 (tazemetostat), a novel EZH2 inhibitor, by the pediatric preclinical testing program (PPTP) by Kurmasheva, Raushan, Cosmopoulos, Kat, Sammons, Melissa, Favours, Edward, Wu, Jianwrong, Houghton, Peter, Smith, Malcolm

“…Background: EZH2 is the functional histone methyltransferase component of the multiprotein complex known as Polycomb Repressive Complex 2 (PRC2). PRC2…”
Get full text

Abstract 1116: Targeting replication stress by carbazole blue- A novel strategy to treat triple negative breast cancers by Rajamanickam, Subapriya, Bates, Kaitlyn, Timilsina, Santosh, Park, JunHyoung, Onyeagucha, Benjamin, Subbarayalu, Panneerdoss, Abdelfattah, Nourhan, Jung, Kwang Hwa, Favours, Edward, Mohammad, Tabrez A., Chen, Hung-I Harry, Kaipparettu, Benny A., Chen, Yidong, Arbiser, Jack L., Rao, Manjeet K

“…Background: Triple-negative breast cancers (TNBC) are the most aggressive forms of breast cancer and almost 60% of patients with TNBCs develop…”
Get full text

Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models by Bandyopadhyay, Abhik, Favours, Edward, Phelps, Doris A., Pozo, Vanessa Del, Ghilu, Samson, Kurmashev, Dias, Michalek, Joel, Trevino, Aron, Guttridge, Denis, London, Cheryl, Hirotani, Kenji, Zhang, Ling, Kurmasheva, Raushan T., Houghton, Peter J.

“…Background Integrating molecularly targeted agents with cytotoxic drugs used in curative treatment of pediatric cancers is complex. An evaluation was…”
Get full text

Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program by Houghton, Peter J., Morton, Christopher L., Kang, Min, Reynolds, C. Patrick, Billups, Catherine A., Favours, Edward, Payne-Turner, Debbie, Tucker, Chandra, Smith, Malcolm A.

“…Treatment with the nucleoside analog cytarabine has been shown to mimic changes in gene expression associated with downregulation of the EWS‐FLI1 oncogene in…”
Get full text